1Taskinen MR. Diabetic dyslipidaemia :from basic research to clinical practice [ J ]. Diabetologia,2003,46:734 - 8.
2Witold PP, Katarzyna W,Tomasz P. Treatment of dyslipidemia in patients with diabetes mellitus [ J ]. Pharmacological Reports, 2005, 57:11.
3Bloomgarden ZT. Perspectives on the news. Approaches to cardiovascular disease and its treatment[ J]. Diabetes Care ,2003,26:3342 -8.
4Lewis GF, Carpentier A, Adeli K, et al. Disordered fat storage and mobilization in the pathogenesis of insulin resistance on type 2 diabetes [ J ]. Endocr Rev,2002,23:201 - 29.
5Chirieac DV,Chirieac LR, Corseni JP, et al. Glucose-stimulated insulin secretion suppresses hepatic triglyceride-rich lipoprotein and apoB production [ J ]. Am J Physiol Endocrinol Metab, 2000,279 : E1003 - 11.
6Vakkilainen J, Mero N, Schweizer A, et al. Effects of nateglinide and glibenclamide on postprandial lipid and glucose metabolism in type 2 diabetes [ J]. Diabetes Metab Res Rev,2002,18:484 - 90.
7Rafael C, Beneridge DJ, Statins D. Statins and diabets[ J]. Seminars in Vascular Medicine,2004,4:322.
8Heine RJ,Dekker JM. Beyond postprandial hyperglycaemia: metabolic factors associated with cardiovascular disease [ J ]. Diabetologia,2002 ,45 :461 -75.
9Ceriello A,Taboga C,Tonutti L,et al. Evidence for an independent and cumulative effect of postprandial hypertriglyceridemia and hyperglycemia on endothelial dysfunction and oxidative stress generation [ J]. Circulation,2002,106 : 1211 - 8.
10Koba S, Hirano T, Yoshino G, et al. Remarkably high prevalence of small dense low-density lipoprotein in Japanese men with coronary artery disease,irrespective of the presence of diabetes [ J ]. Atherosclerosis,2002,160 : 249 - 56.
6Luc G. Mechanisms of action of hypolipidemic agents,Therapie 2000 ; 55 (6) : 661 - 668.
7Chinetti G, Fruchart JC, Staeles B, Peroxisome prolifera-toractivated receptors(PPARs): nuclear receptors with functions in the vascular wall, Z Kardiol 2001;90 Suppl 3:125-132.
8Steinmez A, Fenselau S, Schrezenmeir J. Treatment of dyslipoproteinemia in the metabolic syndrome. Exp Clin Endocrinol Diabetes 2001 ; 109(4) :548- 559.
9Rubbins H B, Roins S J, Collins D, et al. Gemfibrozil for the second prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group,NEngl J Med 1999;341:410-418.
10Goa K L, Barradell L B, Plosker G L, Bezafibrate, and update of its pharmacology and use in the management of dyslipidaemia. Drugs 1996;52(5) :725-753.
